Granules India Ltd. reported a robust performance for the quarter and financial year ended March 31, 2026. The company achieved a 23% YoY growth in Q4 revenue, reaching INR 14,706 Mn. EBITDA surged by 40% YoY to INR 3,521 Mn, while Profit After Tax (PAT) rose by 33% YoY to INR 2,016 Mn, reflecting improved earnings quality and sustained progress in its core pharmaceutical segments.
Financial Performance Highlights
For the quarter ended March 31, 2026, Granules India delivered a strong performance across key financial metrics. Revenue from operations climbed to INR 14,706 Mn, a 23% increase compared to the same period last year. Profitability also saw significant gains, with EBITDA reaching INR 3,521 Mn—a 40% growth YoY—and Profit After Tax (PAT) standing at INR 2,016 Mn, up 33% YoY. On an annual basis for FY26, the company recorded revenue of INR 53,656 Mn with a healthy 25% growth in EBITDA to INR 11,851 Mn.
Strategic Business Growth
The company’s growth is anchored by its diversified product portfolio, with Finished Dosages (FD) contributing 73% of total revenue in the final quarter. API and PFI segments contributed 13% and 9% respectively, while the Peptide/CDMO platform accounted for 5%. Geographically, Europe saw an increased revenue share, rising to 17% in Q4 FY26 from 8% in the same period last year. Management highlighted that the performance was driven by continued portfolio expansion and disciplined execution.
Operational Efficiency and Debt Management
Granules India has demonstrated improved operational efficiency, with ROCE rising to 17.6% in FY26, up from 16.6% in the previous fiscal year. The company also strengthened its balance sheet by reducing net debt to INR 4,021 Mn, a reduction of INR 3,040 Mn compared to Q4 FY25. The net debt to EBITDA ratio currently stands at 0.34x, reflecting a disciplined approach to capital management.
Source: BSE
